Highlights
- Market Cap
- $2.09B
- Enterprise Value
- $2.01B
- EPS (TTM)
- $1.20
- PE Ratio
- 7.93
- Total Revenue (TTM)
- $874.84M
- Gross Profit (TTM)
- $855.43M
- EBITDA (TTM)
- $345.49M
- Year Range
- $6.00 - $11.31
- Target Price
- $14.40
- ROA (TTM)
- 51.32%
- ROE (TTM)
- -221.45%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BioCryst Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
BioCryst Pharmaceuticals, Inc. (BCRX) has returned 22.05% so far this year and 26.93% over the past 12 months. Looking at the last ten years, BCRX has achieved an annualized return of 12.90%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.
BioCryst Pharmaceuticals, Inc.
- 1D
- 0.74%
- 1M
- 8.80%
- YTD
- 22.05%
- 6M
- 25.43%
- 1Y
- 26.93%
- 3Y*
- 4.51%
- 5Y*
- -0.88%
- 10Y*
- 12.90%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 4, 1994, BCRX's average daily return is +0.14%, while the average monthly return is +2.79%. At this rate, your investment would double in approximately 2.1 years.
Historically, 51% of months were positive and 49% were negative. The best month was Jul 2013 with a return of +183.9%, while the worst month was Feb 2016 at -71.5%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.
On a daily basis, BCRX closed higher 45% of trading days. The best single day was Apr 27, 2009 with a return of +75.6%, while the worst single day was Feb 8, 2016 at -71.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.64% | 32.98% | 8.80% | 22.05% | |||||||||
| 2025 | 5.05% | 8.99% | -12.89% | 18.00% | 21.47% | -16.65% | -9.15% | 2.09% | -8.66% | -3.56% | -1.91% | 8.64% | 3.72% |
| 2024 | -11.52% | 6.23% | -9.77% | -18.70% | 56.42% | -4.33% | 17.80% | 19.37% | -12.54% | 5.39% | -6.37% | 0.27% | 25.54% |
| 2023 | -8.10% | -16.11% | -5.76% | -8.75% | 8.67% | -14.87% | 4.97% | -3.79% | -0.42% | -22.46% | 7.10% | 1.87% | -47.82% |
| 2022 | 11.55% | 7.51% | -2.11% | -42.87% | 0.22% | 13.64% | 4.16% | 26.13% | -9.35% | 5.95% | 0.07% | -14.07% | -17.11% |
| 2021 | 14.36% | 26.53% | -5.66% | 14.41% | 35.54% | 0.25% | 1.96% | -1.24% | -9.74% | 3.90% | -19.22% | 14.84% | 85.91% |
Benchmark Metrics
BioCryst Pharmaceuticals, Inc. has an annualized alpha of 28.18%, beta of 1.11, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 07, 1994.
- This stock participated in 143.91% of S&P 500 Index downside but only 117.90% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 28.18%
- Beta
- 1.11
- R²
- 0.06
- Upside Capture
- 117.90%
- Downside Capture
- 143.91%
Return for Risk
Risk / Return Rank
BCRX ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and compare them to a chosen benchmark (S&P 500 Index).
| BCRX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.53 | 0.90 | -0.36 |
Sortino ratioReturn per unit of downside risk | 1.29 | 1.39 | -0.10 |
Omega ratioGain probability vs. loss probability | 1.14 | 1.21 | -0.07 |
Calmar ratioReturn relative to maximum drawdown | 0.48 | 1.40 | -0.92 |
Martin ratioReturn relative to average drawdown | 0.77 | 6.61 | -5.84 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BCRX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioCryst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioCryst Pharmaceuticals, Inc. was 97.74%, occurring on Jul 3, 2002. The portfolio has not yet recovered.
The current BioCryst Pharmaceuticals, Inc. drawdown is 71.26%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.74% | Aug 28, 2000 | 462 | Jul 3, 2002 | — | — | — |
| -75.98% | Jun 20, 1996 | 581 | Oct 7, 1998 | 212 | Aug 11, 1999 | 793 |
| -50.76% | Mar 9, 2000 | 28 | Apr 17, 2000 | 74 | Aug 2, 2000 | 102 |
| -47.17% | Mar 11, 1994 | 28 | Apr 20, 1994 | 225 | Mar 13, 1995 | 253 |
| -40.8% | Jun 19, 1995 | 2 | Jun 20, 1995 | 211 | Apr 19, 1996 | 213 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioCryst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioCryst Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BCRX, comparing it with other companies in the Biotechnology industry. Currently, BCRX has a P/E ratio of 7.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BCRX relative to other companies in the Biotechnology industry. Currently, BCRX has a P/S ratio of 2.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |